Figure 1 describes the Graphical Study Design:

* Additional titration phone calls-only for FRC arm

** Insulin glargine/lixisenatide fixed ratio combination (FRC) treatment will be initiated with the Peach Pen. The initial daily dose to be adminitered will be 10 U: this corresponds to an initial associated dose of insulin glargine 10 U and lixisenatide 5 pg according to the 2/U pg fixed ratio used in the Peach Pen. Afterwards, doses will be individually titrated throughout the study to reach and maintain fasting SMPG: 80-100mg/dL(4.4-6.6 mmol/L) avoiding hypoglycemia.

† Liraglutide, exenatide, albiglutide, or dulaglutide is discontinued at visit 3 for patients randomized to the FRC treatment. Any patient treated with a once weekly GLP-1 RA upon entering the study who is assigned to receive the FRC treatment should not receive their first dose until at least 1 week after their last dose of GLP-1 RA.

Figure 2 describes the plot of mean HbA1c (%) by visit during the 26-week randomized treatment period - mITT population:

S = Screening (Week -2), B = Baseline
FRC = Fixed Ratio Combination, GLP-1 RA = GLP-1 Receptor Agonist
The plot included all scheduled measurements obtained during the 26-week randomized treatment period, including those obtained after IMP discontinuation or introduction of rescue medication.

Figure 3 describes the plot of mean fasting plasma glucose (mmol/L[mg/dL] by visit during the 26-week randomized treatment period - mITT population:

S = Screening (Week -2), B = Baseline
FRC = Fixed Ratio Combination, GLP-1 RA = GLP-1 Receptor Agonist
The analysis included all scheduled measurements obtained during the 26-week randomized treatment period, including those obtained after IMP discontinuation or introduction of rescue medication.

Figure 4 describes the plot of mean 7-point SMPG (mmol/L[mg/dL]) at baseline and Week 26 during the on-treatment period - mITT population:

SMPG = Self-monitored plasma glucose.
FRC = Fixed Ratio Combination, GLP-1 RA=GLP-1 Receptor Agonist
The analysis included all scheduled measurements obtained during the 26-week randomized treatment period, including those obtained after IMP discontinuation or introduction of rescue therapy.